“My doctor added a water pill.” If that pill is furosemide (Lasix), you may wonder whether it is there for your blood pressure, for swelling, or for something about your heart or kidneys. The label allows all of these, but blood pressure guidelines usually reach for a different kind of diuretic first.
Yes, Lasix lowers blood pressure, and its FDA label includes hypertension: oral Lasix “may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.” But US guidelines list thiazide-type diuretics, not loop diuretics like furosemide, among the first-line blood pressure medicines. Furosemide tends to be chosen when there is fluid buildup, heart failure or reduced kidney function.
A diuretic makes the kidneys pass more salt and water. Less fluid in the blood vessels means lower pressure, at least at first. That basic idea applies to every diuretic. The differences lie in where in the kidney each one works, how strong and how long the effect is, and how well it holds up when kidney function declines.
What the Lasix label actually says
The Lasix tablet label on DailyMed lists two uses. The first is edema, meaning fluid buildup, linked to congestive heart failure, cirrhosis of the liver and kidney disease, including nephrotic syndrome. The label adds that Lasix is “particularly useful when an agent with greater diuretic potential is desired.”
The second is hypertension in adults, alone or with other blood pressure drugs. Right after that, the label adds a caveat that explains much of its place in practice: “Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.”
The label also describes the timing. After an oral dose, diuresis begins within 1 hour, peaks in the first or second hour and lasts 6 to 8 hours. That is a strong, fairly short burst. It suits clearing fluid more than providing a steady, all-day effect on blood pressure.
MedlinePlus describes furosemide the same way: it is used alone or with other medicines to treat high blood pressure, and to treat edema. It adds that furosemide controls high blood pressure and edema but does not cure them.
Thiazide-type vs. loop diuretics for blood pressure
The 2017 ACC/AHA high blood pressure guideline named thiazide diuretics, calcium channel blockers, ACE inhibitors and angiotensin receptor blockers as first-line agents, as summarized in American Family Physician. The 2025 AHA/ACC guideline, published August 14, 2025, kept thiazide-type diuretics on that list, according to a 2026 commentary from European Renal Best Practice in Nephrology Dialysis Transplantation. Loop diuretics are not in that first-line group.
| Thiazide-type diuretics (e.g., chlorthalidone, indapamide, hydrochlorothiazide) | Loop diuretics (e.g., furosemide) | |
|---|---|---|
| Place in US blood pressure guidelines | Thiazide diuretics named first-line in 2017; thiazide-type diuretics first-line in 2025 | Not a first-line class for uncomplicated hypertension |
| What the Lasix label says about the comparison | Named as the reference point | Patients not controlled with thiazides will probably not be controlled with Lasix alone |
| Duration of effect | Differs between drugs in the class; not compared here | Lasix label: 6 to 8 hours of diuresis after an oral dose |
| Reduced kidney function | KDIGO 2021: thiazides lose efficacy as GFR worsens, though chlorthalidone, metolazone and indapamide appear to remain effective below 30 | KDIGO 2021: often effective at GFR below 30 |
| Where they fit best | Routine blood pressure treatment, often combined with other classes | Fluid overload in heart failure, kidney disease or liver disease |
The full 2025 guideline text sits behind a publisher page we could not open, so the table relies on the summaries above and on kidney-specific guidance rather than on quoting the guideline’s own drug tables.
Where diuretics sit in the 2025 guideline
The 2025 update did not move loop diuretics into the first-line group, but it changed the surrounding plan in ways that affect how a diuretic gets added. According to the ERBP commentary, the 2025 AHA/ACC guideline recommends starting most people who need medication on a single-pill, once-daily combination of two drugs to improve adherence, except for people with frailty or symptomatic orthostatic hypotension. A third agent is added if blood pressure is still above goal, followed by raising doses to the highest tolerated. For stage 1 hypertension, a single first-line agent with close follow-up is an option.
The commentary adds that the 2025 guideline recommends an ACE inhibitor or an angiotensin receptor blocker as that single agent for people with chronic kidney disease or type 2 diabetes. It also describes a target of a systolic pressure below 130 mm Hg, with encouragement to reach below 120, and a diastolic pressure below 80 for most adults, individualized to the person. A loop diuretic in this framework is usually a tool for a specific problem, such as fluid overload or advanced kidney disease, rather than one of the first building blocks.
That also explains a common surprise. Someone may take furosemide for years for heart failure and still need a separate blood pressure plan, because the two goals do not always line up.
When a loop diuretic is the better fit
Reduced kidney function
The KDIGO 2021 guideline on blood pressure in chronic kidney disease says that thiazide diuretics lose efficacy in diuresis and blood pressure lowering as kidney filtration (GFR) worsens. It adds that loop diuretics are often effective at GFRs below 30 mL/min per 1.73 m². For people with advanced kidney disease and fluid retention, that is a common reason furosemide appears on the list.
The picture has shifted, though. KDIGO notes that several thiazide-type drugs, including chlorthalidone, appear to remain effective at those low GFRs. In the 2021 CLICK trial in the New England Journal of Medicine (Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease), 160 people with stage 4 CKD and poorly controlled blood pressure were randomized to chlorthalidone or placebo. About 60% were already taking loop diuretics. After 12 weeks, 24-hour systolic pressure fell 11.0 mm Hg with chlorthalidone against 0.5 mm Hg with placebo. Low potassium, reversible rises in creatinine, high blood sugar, dizziness and high uric acid were more common with chlorthalidone. Some people end up on both types for that reason.
Heart failure and swelling
Edema from congestive heart failure is the first use the Lasix label lists. In someone with heart failure and high blood pressure, furosemide may be there mainly to keep fluid off the lungs and legs. Any blood pressure drop is then a side benefit rather than the main goal. A change in the dose may follow your weight and symptoms, not your blood pressure readings.
Liver disease
The label also covers edema from cirrhosis and warns that in people with cirrhosis and ascites, Lasix therapy is best started in the hospital. That use is about fluid, not blood pressure.
Already on several blood pressure drugs
The Lasix label tells prescribers that when Lasix is added to other blood pressure medicines, the doses of those other agents should be reduced to prevent an excessive drop. That is a prescriber task. If furosemide was added and you feel lightheaded when you stand, report it rather than adjusting anything yourself.
Older adults
For hypertension, the label advises that dose selection for older patients be cautious, usually starting at the low end of the range, because of a greater chance of reduced kidney, liver or heart function and of other medicines. The clinical pharmacology section also notes that the initial diuretic effect of furosemide is smaller in older subjects than in younger ones. Our caregiver’s watch list for Lasix in older adults covers what family members can look out for.
The label advises frequent checks of electrolytes, particularly potassium, plus CO2, creatinine and BUN, during the first few months of treatment. It also warns that furosemide may raise blood sugar and make skin more sensitive to sunlight. Our guide to Lasix side effects, dehydration and electrolytes covers the warning signs, and our comparison of Bumex, torsemide and Lasix explains how the loop diuretics differ.
Reading your own numbers
Because the effect of an oral dose is concentrated in the first hours, home readings can look different depending on when you measure relative to the pill. Keep a log with the time of the dose and the time of each reading so your clinician can make sense of the pattern. MedlinePlus advises continuing to take furosemide even if you feel well. Our guide to why blood pressure differs each time you measure explains how to take consistent home readings. The Lasix label also reminds people with hypertension to avoid products that can raise blood pressure, including some over-the-counter appetite suppressants and cold medicines.
Some medicines blunt furosemide. The label says sucralfate can reduce its antihypertensive effect, so the two should be separated by at least two hours. It also says indomethacin can reduce its effects in some people. Tell your prescriber about any anti-inflammatory painkillers you take.
Questions to ask your clinician
- Is furosemide in my plan mainly for blood pressure, for swelling, or for my heart or kidneys?
- Why a loop diuretic rather than a thiazide-type diuretic in my case?
- What is my latest kidney function (eGFR), and does it affect which diuretic works for me?
- Do my other blood pressure medicines need to change now that furosemide has been added?
- When should my potassium and kidney blood tests be checked?
- What time of day should I measure blood pressure at home, and should I log my weight too?
- Which symptoms, such as dizziness on standing, muscle cramps or very low urine output, should make me call?
Sources
- DailyMed: Lasix (furosemide) tablets label
- MedlinePlus: Furosemide
- American Family Physician 2018: ACC/AHA releases updated high blood pressure guideline
- 2025 AHA/ACC high blood pressure guideline (Hypertension, record on Europe PMC)
- Nephrol Dial Transplant 2026: ERBP commentary on the 2025 AHA/ACC guideline
- KDIGO 2021 guideline: blood pressure in chronic kidney disease
- NEJM 2021: Chlorthalidone for hypertension in advanced CKD (CLICK)
Evidence checked November 2, 2026. The full 2025 AHA/ACC guideline text could not be opened; first-line drug classes were confirmed through published summaries.